p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, Barba M.
Vici P, et al. Among authors: esposito l.
Oncotarget. 2014 Nov 15;5(21):10382-92. doi: 10.18632/oncotarget.2060.
Oncotarget. 2014.
PMID: 25071015
Free PMC article.